ReviewTheranostics2021
Smart magnetic resonance imaging-based theranostics for cancer.
Review in Theranostics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 80 citations in OpenAlex.
- Beyond radiotheranostics: how imaging modality defines theranostics.European radiology experimental · 2026Review
- Advances in research on layered double hydroxides for biomedical applications.Smart molecules : open access · 2026Review
- Smart Immunomodulating Nanocomposites Enabling on-Demand Solid Tumor Treatment With Quasi-Real-Time Response Monitoring.Advanced healthcare materials · 2026Article
- Multifunctional Nano-Contrast Agent Carriers: From Traditional Platforms to Next-Generation Theranostic Applications in Molecular Imaging.Biomedicines · 2026Review
- Artificial intelligence-assisted design and optimization of stimuli-responsive nanocarriers for smart drug delivery.Materials today. Bio · 2026Review
- Two-step distance tuning of TMaterials today. Bio · 2026Article
- Multinuclear NMR and MRI Beyond Proton Imaging: Principles, Contrast Mechanisms, and Applications in Materials and Biomedicine.International journal of molecular sciences · 2026Review
- Biomaterials' Role in Improving Patient Care from Drug Testing and Delivery to Theragnostics and Regenerative Medicine.Journal of functional biomaterials · 2026Review
- Antibacterial hydrogels for skin infected wounds: frontier approaches as antibiotic alternatives therapy.Frontiers in cellular and infection microbiology · 2026Review
- Challenges and Opportunities in Radioligand Therapy.Journal of nuclear medicine technology · 2025Review
- Advanced nanotheranostic approaches for targeted glioblastoma treatment: a synergistic fusion of CRISPR-Cas gene editing, AI-driven tumor profiling, and BBB-modulation.Medical oncology (Northwood, London, England) · 2025Review
- Pt(IV)-functionalised polyacrylic acid-coated iron oxide magnetic nanoparticles as redox-responsive cancer theranostics.Journal of materials chemistry. B · 2025Article
- Molecular theranostics: principles, challenges and controversies.Journal of medical radiation sciences · 2025Review
- Carrier-free nanoparticles for cancer theranostics with dual-mode magnetic resonance imaging/fluorescence imaging and combination photothermal and chemodynamic therapy.International journal of pharmaceutics · 2025Article
- Engineering Stimuli-Responsive Materials for Precision Medicine.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- The role of manganese-based MRI contrast agents for cancer theranostics: Where do we stand in 2025?Theranostics · 2025Review
- Application of rare earth elements in dual-modality molecular probes.RSC advances · 2024Review
- Stimuli-responsive linkers and their application in molecular imaging.Exploration (Beijing, China) · 2024Review
- MR beyond diagnostics at the ESMRMB annual meeting: MR theranostics and intervention.Magma (New York, N.Y.) · 2024Article
- Biocompatible and bioactivable terpolymer-lipid-MnOMaterials today. Bio · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Smart theranostics are dynamic platforms that integrate multiple functions, including at least imaging, therapy, and responsiveness, in a single agent. This review showcases a variety of responsive theranostic agents developed specifically for magnetic resonance imaging (MRI), due to the privileged position this non-invasive, non-ionising imaging modality continues to hold within the clinical imaging field. Different MRI smart theranostic designs have been devised in the search for more efficient cancer therapy, and improved diagnostic efficiency, through the increase of the local concentration of therapeutic effectors and MRI signal intensity in pathological tissues. This review explores novel small-molecule and nanosized MRI theranostic agents for cancer that exhibit responsiveness to endogenous (change in pH, redox environment, or enzymes) or exogenous (temperature, ultrasound, or light) stimuli. The challenges and obstacles in the design and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.